EXAI News and Press, Exscientia Limited From 02/17/23

Summary AI has begun to make headways in the field of drug discovery and development. Exscientia offers investors direct exposure to this wave of innovation. The company has attracted risk capital to unlock for sophisticated investors already. Net-net, rate buy. Invest...

- EXS4318 is the first immunology & inflammation candidate designed by Exscientia and its fourth molecule to enter the clinic - - Exscientia invented a potentially first-in-class potent and selective PKC theta inhibitor - - Eligible for pre-commercial milestone payments and, i...

Summary SDGR's valuable segment is its software business which represents majority of the revenue. There is an increasing demand for AI/ML capabilities by biopharmaceutical companies. SDGR's differentiated product stemmed from years of data processing. For furt...

Uses multi-omics to identify a biomarker which could be predictive of '546 response in the clinic Differentiated '546 development and patient enrichment strategy driven by Exscientia's precision medicine platform Research highlights the relationship between Exscientia's high adeno...

— Study will enrol up to 110 patients in immunotherapy relapsed/refractory RCC and NSCLC — — Exscientia’s A 2A biomarker signature for patient selection will be prospectively tested during the trial — – CTA for GTAEXS-6...

Exscientia plc (EXAI) Q3 2022 Earnings Conference Call November 15, 2022 08:30 AM ET Company Participants Sara Sherman - Vice President-Investor Relations Andrew Hopkins - Chief Executive Officer & Executive Director Ben Taylor - Chief Financial Officer &...

The following slide deck was published by Exscientia plc in conjunction with their 2022 Q3 earnings call. For further details see: Exscientia plc 2022 Q3 - Results - Earnings Call Presentation

Exscientia press release ( NASDAQ: EXAI ): Q3 GAAP EPS of -$0.32. Revenue of $7M (-64.3% Y/Y). For further details see: Exscientia GAAP EPS of -$0.32, revenue of $7M

Exscientia plc (Nasdaq: EXAI) Recent developments in the Company’s pipeline, collaborations, and operations, as well as financial results for the third quarter 2022, are summarised below. Exscientia will host a conference call today, November 15, at 1:30 p.m. GMT / 8:30 a.m...

Effort aligns MD Anderson’s drug development expertise with Exscientia’s AI-driven patient-first precision medicine and drug discovery platforms Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic ...